title: Exploiting tumor vulnerabilities: epigenetics, cancer metabolism and the mTOR pathway in the era of personalized medicine.
abstract: Patient stratification according to drug responses, together with the discovery of novel antitumor targets, is leading to a new era of personalized cancer treatments. With the aim of identifying emerging pathways and the challenges faced by clinicians during clinical trials, the IDIBELL Cancer Conference on Personalized Cancer Medicine took place in Barcelona on December 3-4, 2012. This conference brought together speakers working in different areas of cancer research (epigenetics, metabolism and the mTOR pathway, cell death and the immune system, clinical oncology) to discuss the latest developments in personalized cancer medicine.
authors.affiliation: Cell Death Regulation Group, School of Medicine, University of Barcelona; and Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain.
authors.forename: Cristina
authors.initials: C
authors.lastname: Muñoz-Pinedo
authors.forename: Eva
authors.initials: E
authors.lastname: González-Suárez
authors.forename: Anna
authors.initials: A
authors.lastname: Portela
authors.forename: Antonio
authors.initials: A
authors.lastname: Gentilella
authors.forename: Manel
authors.initials: M
authors.lastname: Esteller
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D044127:Epigenesis, Genetic / Q000187:drug effects / Q000235:genetics; D057890:Epigenomics / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism*; D057285:Precision Medicine / Q000379:methods*; D058570:TOR Serine-Threonine Kinases / Q000235:genetics* / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases